Tiziana Life Sciences (TLSA) said Tuesday it filed an investigational new drug application for foralumab, a potential treatment for amyotrophic lateral sclerosis, with the US Food and Drug Administration.
The application is supported by a grant from the ALS Association as part of the Hoffman ALS Clinical Trial Awards Program, the company said.
The company's development programs for Foralumab, a nasal anti-CD3 monoclonal antibody, are also being focused on multiple sclerosis and Alzheimer's disease.
Upon getting the agency's clearance, Tiziana said it plans to begin a 20-patient clinical trial of two doses of intranasal foralumab aimed at evaluating the safety and early-stage parameters of disease improvement in amyotrophic lateral sclerosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.